Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Sell
43
GRCE Quote, Financials, Valuation and Earnings
Last price:
$2.84
Seasonality move
:
-4.31%
Day range:
$2.80 - $2.98
52-week range:
$1.75 - $4.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.75x
Volume:
35.1K
Avg. volume:
36.7K
1-year change:
-12.2%
Market cap:
$39M
Revenue:
--
EPS (TTM):
-$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics
|
-- | -$0.25 | -- | -7.33% | $11.93 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.36 | -100% | -7.24% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics
|
$2.84 | $11.93 | $39M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.49 | $5.00 | $46.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.60 | $0.85 | $3.5M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.51 | -- | $24.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$4.36 | $1.00 | $3.1M | -- | $0.00 | 0% | 1.40x |
|
TOVX
Theriva Biologics
|
$0.50 | $7.00 | $4.1M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GRCE
Grace Therapeutics
|
-- | 1.301 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.250 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.941 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.642 | -- | -- |
|
OGEN
Oragenics
|
-- | -1.150 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.651 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GRCE
Grace Therapeutics
|
-- | -$3.7M | -- | -- | -- | -$4.1M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Grace Therapeutics vs. Competitors
-
Which has Higher Returns GRCE or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Grace Therapeutics's net margin of -11511.11%. Grace Therapeutics's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics-- -$0.36 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About GRCE or ATNM?
Grace Therapeutics has a consensus price target of $11.93, signalling upside risk potential of 319.96%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 235.57%. Given that Grace Therapeutics has higher upside potential than Actinium Pharmaceuticals, analysts believe Grace Therapeutics is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics2 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is GRCE or ATNM More Risky?
Grace Therapeutics has a beta of 0.893, which suggesting that the stock is 10.739% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.271, suggesting its less volatile than the S&P 500 by 127.061%.
-
Which is a Better Dividend Stock GRCE or ATNM?
Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or ATNM?
Grace Therapeutics quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Grace Therapeutics's net income of -$4.2M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics-- -- -- -$4.2M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns GRCE or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Grace Therapeutics's net margin of -49.65%. Grace Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics-- -$0.36 -- NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About GRCE or NBY?
Grace Therapeutics has a consensus price target of $11.93, signalling upside risk potential of 319.96%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Grace Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Grace Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics2 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is GRCE or NBY More Risky?
Grace Therapeutics has a beta of 0.893, which suggesting that the stock is 10.739% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.
-
Which is a Better Dividend Stock GRCE or NBY?
Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or NBY?
Grace Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Grace Therapeutics's net income of -$4.2M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics-- -- -- -$4.2M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns GRCE or NNVC?
Nanoviricides has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics-- -$0.36 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About GRCE or NNVC?
Grace Therapeutics has a consensus price target of $11.93, signalling upside risk potential of 319.96%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that Nanoviricides has higher upside potential than Grace Therapeutics, analysts believe Nanoviricides is more attractive than Grace Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics2 0 0 NNVCNanoviricides0 0 0 -
Is GRCE or NNVC More Risky?
Grace Therapeutics has a beta of 0.893, which suggesting that the stock is 10.739% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.
-
Which is a Better Dividend Stock GRCE or NNVC?
Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or NNVC?
Grace Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is lower than Nanoviricides's net income of -$2.2M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics-- -- -- -$4.2M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns GRCE or OGEN?
Oragenics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics-- -$0.36 -- OGENOragenics-- -$3.60 -- -
What do Analysts Say About GRCE or OGEN?
Grace Therapeutics has a consensus price target of $11.93, signalling upside risk potential of 319.96%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 588.14%. Given that Oragenics has higher upside potential than Grace Therapeutics, analysts believe Oragenics is more attractive than Grace Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics2 0 0 OGENOragenics0 1 0 -
Is GRCE or OGEN More Risky?
Grace Therapeutics has a beta of 0.893, which suggesting that the stock is 10.739% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.
-
Which is a Better Dividend Stock GRCE or OGEN?
Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or OGEN?
Grace Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is lower than Oragenics's net income of -$2.2M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics-- -- -- -$4.2M OGENOragenics1.40x -- -- -$2.2M
-
Which has Higher Returns GRCE or TOVX?
Theriva Biologics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GRCEGrace Therapeutics-- -$0.36 -- TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About GRCE or TOVX?
Grace Therapeutics has a consensus price target of $11.93, signalling upside risk potential of 319.96%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1301.12%. Given that Theriva Biologics has higher upside potential than Grace Therapeutics, analysts believe Theriva Biologics is more attractive than Grace Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings GRCEGrace Therapeutics2 0 0 TOVXTheriva Biologics1 1 0 -
Is GRCE or TOVX More Risky?
Grace Therapeutics has a beta of 0.893, which suggesting that the stock is 10.739% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.
-
Which is a Better Dividend Stock GRCE or TOVX?
Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GRCE or TOVX?
Grace Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is higher than Theriva Biologics's net income of -$4.3M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GRCEGrace Therapeutics-- -- -- -$4.2M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Gamestop’s Bitcoin Strategy Going To Succeed?
When GameStop (NYSE: GME) announced in Q1 that its board had…
How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 14
VEON [VEON] is down 18.57% over the past day.
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
